Compare Aventis Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CIPLA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CIPLA SANOFI INDIA/
CIPLA
 
P/E (TTM) x 39.1 23.5 166.5% View Chart
P/BV x 7.0 2.6 270.8% View Chart
Dividend Yield % 1.2 0.6 199.9%  

Financials

 SANOFI INDIA   CIPLA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
CIPLA
Mar-19
SANOFI INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs6,840678 1,008.9%   
Low Rs4,630484 957.0%   
Sales per share (Unadj.) Rs1,203.1198.2 607.0%  
Earnings per share (Unadj.) Rs165.318.5 892.2%  
Cash flow per share (Unadj.) Rs209.935.0 599.8%  
Dividends per share (Unadj.) Rs84.003.00 2,800.0%  
Dividend yield (eoy) %1.50.5 283.6%  
Book value per share (Unadj.) Rs963.6186.3 517.2%  
Shares outstanding (eoy) m23.03805.70 2.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.82.9 162.7%   
Avg P/E ratio x34.731.4 110.7%  
P/CF ratio (eoy) x27.316.6 164.6%  
Price / Book Value ratio x6.03.1 190.9%  
Dividend payout %50.816.2 313.8%   
Avg Mkt Cap Rs m132,078468,031 28.2%   
No. of employees `0003.322.6 14.6%   
Total wages/salary Rs m4,06828,565 14.2%   
Avg. sales/employee Rs Th8,393.87,053.1 119.0%   
Avg. wages/employee Rs Th1,232.41,261.5 97.7%   
Avg. net profit/employee Rs Th1,153.0659.1 174.9%   
INCOME DATA
Net Sales Rs m27,708159,710 17.3%  
Other income Rs m8974,766 18.8%   
Total revenues Rs m28,605164,475 17.4%   
Gross profit Rs m6,23530,973 20.1%  
Depreciation Rs m1,02713,263 7.7%   
Interest Rs m71,684 0.4%   
Profit before tax Rs m6,09820,791 29.3%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2925,695 40.2%   
Profit after tax Rs m3,80614,924 25.5%  
Gross profit margin %22.519.4 116.0%  
Effective tax rate %37.627.4 137.2%   
Net profit margin %13.79.3 147.0%  
BALANCE SHEET DATA
Current assets Rs m15,922124,266 12.8%   
Current liabilities Rs m6,23537,715 16.5%   
Net working cap to sales %35.054.2 64.5%  
Current ratio x2.63.3 77.5%  
Inventory Days Days6491 70.2%  
Debtors Days Days2195 22.0%  
Net fixed assets Rs m7,539105,190 7.2%   
Share capital Rs m2301,611 14.3%   
"Free" reserves Rs m21,962148,511 14.8%   
Net worth Rs m22,192150,123 14.8%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m29,839239,633 12.5%  
Interest coverage x872.113.3 6,535.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.7 139.3%   
Return on assets %12.86.9 184.4%  
Return on equity %17.29.9 172.5%  
Return on capital %27.511.8 232.4%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58757,410 13.2%   
Fx outflow Rs m7,14519,041 37.5%   
Net fx Rs m44238,368 1.2%   
CASH FLOW
From Operations Rs m3,73916,911 22.1%  
From Investments Rs m-731-16,687 4.4%  
From Financial Activity Rs m-1,972-3,487 56.5%  
Net Cashflow Rs m1,036-3,451 -30.0%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 60.4 20.8 290.4%  
Indian inst/Mut Fund % 14.4 12.2 118.0%  
FIIs % 14.6 23.7 61.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   15,184 161,166 9.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   SUVEN LIFESCIENCES  SHASUN PHARMA  NOVARTIS  TTK HEALTHCARE  SUN PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Scales 42,000 and Smallcaps Rebound: What Happens Next?(Podcast)

This week, the BSE Sensex crossed 42,000 level for the first time. While Nifty followed suit, hitting a record high of 12,377.

Related Views on News

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 0.3% (Market Updates)

Jan 17, 2020 | Updated on Jan 17, 2020

DIVIS LABORATORIES share price has hit an all time high at Rs 1,915 (up 0.4%). The BSE HEALTHCARE Index is up by 0.3%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 0.4%) and ABBOTT INDIA . The top losers include ALKEM LABORATORIES (down 0.2%) and SUN PHARMA ADV. RES. (down 0.2%).

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Jan 17, 2020 | Updated on Jan 17, 2020

DIVIS LABORATORIES share price has hit an all time high at Rs 1,908 (up 0.5%). The BSE HEALTHCARE Index is up by 0.1%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 0.5%) and SANOFI INDIA (up 0.1%). The top losers include CIPLA (down 0.1%) and GLENMARK PHARMA (down 0.2%).

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Jan 6, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

I Made a Killing in the Markets this Week... Here's How(Profit Hunter)

Jan 10, 2020

How we made a killing in the markets amidst geopolitical tension and war mongering.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jan 17, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS